May 7, 2025
Mozart Therapeutics Presents Preclinical Data Showing Restoration of CD8 Treg Functionality in Type 1 Diabetes and Early Data from their Targeted IL-15 Program at Immunology 2025™
March 17, 2025
Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg
February 6, 2025
Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn’s and Colitis Congress®
November 7, 2024
Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis
November 5, 2024
Mozart Therapeutics Announces Podium Presentation at Immunology of Diabetes Society Congress; Shows Potential for Lead Program, MTX-101, to Restore Insulin Production in Type 1 Diabetes
June 21, 2024
Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions
June 17, 2024
Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Study of MTX-101, in Development for Treatment of Autoimmune Diseases
May 3, 2024
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024
March 14, 2024
Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024
November 13, 2023
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
October 30, 2023
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer
Gerold Nepom, MD, PhD joins Scientific Advisory Board
June 21, 2023
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting
June 7, 2023
Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases
May 25, 2023
Mozart Therapeutics Announces Poster Presentation at FOCIS 2023 Annual Meeting
May 15, 2023
Mozart Therapeutics Highlights Promising Preclinical Activity of Novel CD8 Treg Network Modulator for Treatment of Autoimmune Diseases in Presentations at IMMUNOLOGYTM 2023
April 25, 2023
Mozart Therapeutics to Present Research on Novel CD8 T Cell Network at Upcoming Meetings: Digestive Disease Week® 2023 (DDW 2023) and IMMUNOLOGY 2023TM AAI Annual Meeting
May 18, 2022
Mozart Therapeutics to Present on Novel CD8 T Cell Network at the 2022 Digestive Disease Week® (DDW) Conference
May 10, 2022
Mozart Therapeutics Presents Data at IMMUNOLOGY™ 2022 Highlighting Novel CD8 Treg Network in Celiac Disease and Other Autoimmune Diseases
October 26, 2021
Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases
